NASDAQ:ELDN Eledon Pharmaceuticals (ELDN) Stock Price, News & Analysis → Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years (From Banyan Hill Publishing) (Ad) Free ELDN Stock Alerts $2.31 -0.09 (-3.75%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$2.18▼$2.4450-Day Range$1.54▼$2.4452-Week Range$1.07▼$2.90Volume197,005 shsAverage Volume288,325 shsMarket Capitalization$57.31 millionP/E RatioN/ADividend YieldN/APrice Target$11.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Eledon Pharmaceuticals alerts: Email Address Eledon Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside405.1% Upside$11.67 Price TargetShort InterestHealthy0.14% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.85Based on 25 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.37) to ($0.43) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.21 out of 5 starsMedical Sector350th out of 925 stocksPharmaceutical Preparations Industry158th out of 430 stocks 3.5 Analyst's Opinion Consensus RatingEledon Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEledon Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Eledon Pharmaceuticals' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.14% of the outstanding shares of Eledon Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverEledon Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Eledon Pharmaceuticals has recently increased by 13.83%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldEledon Pharmaceuticals does not currently pay a dividend.Dividend GrowthEledon Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ELDN. Previous Next 3.8 News and Social Media Coverage News SentimentEledon Pharmaceuticals has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 25 news articles for Eledon Pharmaceuticals this week, compared to 1 article on an average week.Search Interest8 people have searched for ELDN on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat Follows5 people have added Eledon Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Eledon Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders19.40% of the stock of Eledon Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions56.77% of the stock of Eledon Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Eledon Pharmaceuticals' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Eledon Pharmaceuticals are expected to grow in the coming year, from ($1.37) to ($0.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Eledon Pharmaceuticals is -1.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Eledon Pharmaceuticals is -1.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEledon Pharmaceuticals has a P/B Ratio of 0.67. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Eledon Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)Watch my video for all of the details About Eledon Pharmaceuticals Stock (NASDAQ:ELDN)Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.Read More ELDN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ELDN Stock News HeadlinesMay 11, 2024 | americanbankingnews.comEledon Pharmaceuticals, Inc. to Post Q1 2024 Earnings of ($0.35) Per Share, HC Wainwright Forecasts (NASDAQ:ELDN)May 10, 2024 | markets.businessinsider.comEledon Pharmaceuticals’ Tegoprubart Shows Promising Trial Results and Fuels Buy RatingMay 12, 2024 | Banyan Hill Publishing (Ad)Forget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)May 10, 2024 | americanbankingnews.comHC Wainwright Weighs in on Eledon Pharmaceuticals, Inc.'s Q2 2024 Earnings (NASDAQ:ELDN)May 9, 2024 | finanznachrichten.deEledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial ResultsMay 9, 2024 | globenewswire.comEledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial ResultsMay 9, 2024 | globenewswire.comEledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant CongressMay 8, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN), Eledon Pharmaceuticals (ELDN) and Agenus (AGEN)May 12, 2024 | Banyan Hill Publishing (Ad)Forget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)May 8, 2024 | americanbankingnews.comEledon Pharmaceuticals (NASDAQ:ELDN) Price Target Raised to $16.00 at HC WainwrightMay 7, 2024 | finanznachrichten.deEledon Pharmaceuticals, Inc.: Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant RejectionMay 7, 2024 | markets.businessinsider.comEledon Pharmaceuticals’ Tegoprubart Shows Promising Clinical Advancements, Reinforcing Buy Rating and Elevated Price TargetMay 7, 2024 | msn.comNano-Cap Eledon Pharmaceuticals' Investigational Drug Shows Safety In Early Organ Transplant Study, Analyst Boosts Forecast On Increased ConfidenceMay 7, 2024 | finance.yahoo.comEledon Pharmaceuticals Announces Oversubscribed $50 Million Private PlacementMay 7, 2024 | globenewswire.comEledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant RejectionMay 2, 2024 | americanbankingnews.comEledon Pharmaceuticals (NASDAQ:ELDN) Shares Down 4.2% April 29, 2024 | msn.com2 Penny Stocks That Wall Street Predicts Will Soar Over 300%March 29, 2024 | finanznachrichten.deEledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial ResultsMarch 29, 2024 | msn.comELDN Stock Earnings: Eledon Pharma Beats EPS for Q4 2023March 28, 2024 | globenewswire.comEledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial ResultsMarch 25, 2024 | globenewswire.comEledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ RejectionMarch 25, 2024 | markets.businessinsider.comEledon Pharmaceuticals’ Tegoprubart Shows Best-in-Class Potential in Organ TransplantationMarch 21, 2024 | msn.comKidney Transplant From Genetically Edited Pig: Boston Patient With End-Stage Renal Disease Becomes First To ReceiveMarch 21, 2024 | finance.yahoo.comEledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a HumanFebruary 19, 2024 | finance.yahoo.comEledon Pharmaceuticals, Inc. (ELDN)February 17, 2024 | morningstar.comEledon Pharmaceuticals Inc ELDNFebruary 13, 2024 | globenewswire.comEledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)See More Headlines Receive ELDN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eledon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2024Today5/12/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ELDN CUSIPN/A CIK1404281 Webnovustherapeutics.com Phone(949) 238-8090FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Stock Price Target$11.67 High Stock Price Target$16.00 Low Stock Price Target$9.00 Potential Upside/Downside+405.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-40,330,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-43.52% Return on Assets-40.95% Debt Debt-to-Equity RatioN/A Current Ratio14.41 Quick Ratio14.41 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.45 per share Price / Book0.67Miscellaneous Outstanding Shares24,810,000Free Float19,999,000Market Cap$57.31 million OptionableOptionable Beta0.86 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. David-Alexandre C. Gros M.D. (Age 52)Ph.D., CEO & Non Independent Director Comp: $807.96kDr. Steven N. Perrin Ph.D. (Age 58)President, Chief Scientific Officer & Non Independent Director Comp: $603.9kMr. Paul Sean Little (Age 59)CFO & Principal Accounting Officer Comp: $611.71kMr. John HerbergerVice President of Technical OperationsMr. Bryan E. Smith J.D. (Age 44)General Counsel, Corporate Secretary & Chief Compliance Officer Comp: $377.14kDr. David Hovland Ph.D.Chief Regulatory OfficerDr. Eliezer Katz F.A.C.S.FACS, M.D., Chief Medical OfficerMore ExecutivesKey CompetitorsNeos TherapeuticsNASDAQ:NEOSBioLineRxNASDAQ:BLRXCelularityNASDAQ:CELUReneo PharmaceuticalsNASDAQ:RPHMAnnovis BioNYSE:ANVSView All CompetitorsInstitutional OwnershipVanguard Group Inc.Bought 273,703 shares on 5/10/2024Ownership: 3.906%Armistice Capital LLCBought 365,000 shares on 2/13/2024Ownership: 9.045%View All Institutional Transactions ELDN Stock Analysis - Frequently Asked Questions Should I buy or sell Eledon Pharmaceuticals stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eledon Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ELDN shares. View ELDN analyst ratings or view top-rated stocks. What is Eledon Pharmaceuticals' stock price target for 2024? 3 Wall Street research analysts have issued 12 month price objectives for Eledon Pharmaceuticals' shares. Their ELDN share price targets range from $9.00 to $16.00. On average, they anticipate the company's share price to reach $11.67 in the next year. This suggests a possible upside of 405.1% from the stock's current price. View analysts price targets for ELDN or view top-rated stocks among Wall Street analysts. How have ELDN shares performed in 2024? Eledon Pharmaceuticals' stock was trading at $1.80 at the beginning of 2024. Since then, ELDN shares have increased by 28.3% and is now trading at $2.31. View the best growth stocks for 2024 here. When is Eledon Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our ELDN earnings forecast. How were Eledon Pharmaceuticals' earnings last quarter? Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) released its quarterly earnings results on Thursday, March, 28th. The company reported ($0.29) earnings per share for the quarter, beating analysts' consensus estimates of ($0.38) by $0.09. Who are Eledon Pharmaceuticals' major shareholders? Eledon Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.91%). Insiders that own company stock include David-Alexandre C Gros, David-Alexandre C Gros and Paul Sean Little. View institutional ownership trends. How do I buy shares of Eledon Pharmaceuticals? Shares of ELDN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ELDN) was last updated on 5/12/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsCollapse of the Petrodollar Colonial MetalsGold Set to EXPLODE!Gold Safe ExchangeShocking: One AI startup's revenue could surge 4,735%Manward Press[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICHe Is Giving Away BitcoinCrypto Swap ProfitsElon to Transform U.S. Economy? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eledon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
